Demographic and medical characteristics of tested patients and the sample of patients screened but not tested
. | Consented and tested more than once* . | Screened for eligibility but not tested . | P . |
|---|---|---|---|
| No. | 142 | 181 | |
| Age | |||
| Mean, y (SD) | 41.48 (9.26) | 42.75 (9.41) | .23 |
| Range, y | 22-61 | 23-65 | |
| Sex, no. (%) | |||
| Male | 69 (49) | 114 (63) | |
| Female | 73 (51) | 67 (37) | |
| Ethnicity or race, no. (%) | |||
| White, non-Hispanic | 135 (95) | 154 (85) | |
| Hispanic and/or nonwhite | 7 (5) | 27 (15) | |
| Educational status, no. (%) | |||
| No high school degree | 1 (0.7) | NA | |
| High school degree or GED | 47 (33) | NA | |
| 2-year college or trade | 23 (16) | NA | |
| 4-year college | 40 (28) | NA | |
| After baccalaureate | 31 (22) | NA | |
| Diagnosis and stage, no. (%) | |||
| CML chronic phase | 59 (42) | 44 (24) | .002 |
| CML accelerated or blast crisis | 11 (8) | 13 (7) | .85 |
| Acute leukemia in remission | 20 (14) | 26 (14) | .94 |
| Acute leukemia in relapse or de novo | 10 (7) | 45 (25) | < .001 |
| Myelodysplasias | 18 (13) | 23 (13) | .86 |
| Lymphoma | 15 (11) | 14 (8) | .65 |
| Multiple myeloma | 6 (4) | 12 (7) | .35 |
| CLL | 3 (2) | 3 (2) | .76 |
| Source of stem cells, no. (%) | .31 | ||
| Bone marrow | 120 (85) | 146 (81) | |
| Peripheral blood | 21 (15) | 35 (19) | |
| Umbilical cord blood | 1 (0.7) | 0 | |
| Conditioning regimen included total body irradiation, no. (%) | 89 (63) | 120 (66) | .50 |
| History of cranial irradiation or intrathecal chemotherapy, no. (%)† | 16 (12) | NA | |
| History of systemic chemotherapy before HCT, no. (%) | |||
| Hydroxyurea only or none | 68 (48) | NA | |
| Interferon with or without hydroxyurea | 17 (12) | NA | |
| Chemotherapy other than hydroxyurea or interferon | 57 (40) | NA | |
| Survivors on systemic chronic GVHD medication at 1 year, no. (%)‡ | 65 (70) | NA | |
| On cyclosporine, tacrolimus, or mycophenolate mofetil‡ | 55 (59) | NA | |
| On glucocorticoids‡ | 55 (59) | NA | |
| On 1 or more systemic chronic GVHD medication at 1 year‡ | 65 (70) | NA |
. | Consented and tested more than once* . | Screened for eligibility but not tested . | P . |
|---|---|---|---|
| No. | 142 | 181 | |
| Age | |||
| Mean, y (SD) | 41.48 (9.26) | 42.75 (9.41) | .23 |
| Range, y | 22-61 | 23-65 | |
| Sex, no. (%) | |||
| Male | 69 (49) | 114 (63) | |
| Female | 73 (51) | 67 (37) | |
| Ethnicity or race, no. (%) | |||
| White, non-Hispanic | 135 (95) | 154 (85) | |
| Hispanic and/or nonwhite | 7 (5) | 27 (15) | |
| Educational status, no. (%) | |||
| No high school degree | 1 (0.7) | NA | |
| High school degree or GED | 47 (33) | NA | |
| 2-year college or trade | 23 (16) | NA | |
| 4-year college | 40 (28) | NA | |
| After baccalaureate | 31 (22) | NA | |
| Diagnosis and stage, no. (%) | |||
| CML chronic phase | 59 (42) | 44 (24) | .002 |
| CML accelerated or blast crisis | 11 (8) | 13 (7) | .85 |
| Acute leukemia in remission | 20 (14) | 26 (14) | .94 |
| Acute leukemia in relapse or de novo | 10 (7) | 45 (25) | < .001 |
| Myelodysplasias | 18 (13) | 23 (13) | .86 |
| Lymphoma | 15 (11) | 14 (8) | .65 |
| Multiple myeloma | 6 (4) | 12 (7) | .35 |
| CLL | 3 (2) | 3 (2) | .76 |
| Source of stem cells, no. (%) | .31 | ||
| Bone marrow | 120 (85) | 146 (81) | |
| Peripheral blood | 21 (15) | 35 (19) | |
| Umbilical cord blood | 1 (0.7) | 0 | |
| Conditioning regimen included total body irradiation, no. (%) | 89 (63) | 120 (66) | .50 |
| History of cranial irradiation or intrathecal chemotherapy, no. (%)† | 16 (12) | NA | |
| History of systemic chemotherapy before HCT, no. (%) | |||
| Hydroxyurea only or none | 68 (48) | NA | |
| Interferon with or without hydroxyurea | 17 (12) | NA | |
| Chemotherapy other than hydroxyurea or interferon | 57 (40) | NA | |
| Survivors on systemic chronic GVHD medication at 1 year, no. (%)‡ | 65 (70) | NA | |
| On cyclosporine, tacrolimus, or mycophenolate mofetil‡ | 55 (59) | NA | |
| On glucocorticoids‡ | 55 (59) | NA | |
| On 1 or more systemic chronic GVHD medication at 1 year‡ | 65 (70) | NA |